Interesting_老虎社区_美港股上老虎

2021-03-19

Interesting

Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?<blockquote>这只被低估的Cathie Wood股票现在比特斯拉更值得买入吗？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":350922374,"tweetId":"350922374","gmtCreate":1616152378798,"gmtModify":1634526983941,"author":{"id":3571297325761462,"idStr":"3571297325761462","authorId":3571297325761462,"authorIdStr":"3571297325761462","name":"Qcumber","avatar":"https://static.tigerbbs.com/9e2e57e4f4eb4b7a08112e384eefa293","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Interesting</body></html>","htmlText":"<html><head></head><body>Interesting</body></html>","text":"Interesting","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/350922374","repostId":1197074607,"repostType":4,"repost":{"id":"1197074607","kind":"news","pubTimestamp":1616152229,"share":"https://www.laohu8.com/m/news/1197074607?lang=zh_CN&edition=full","pubTime":"2021-03-19 19:10","market":"us","language":"en","title":"Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?<blockquote>这只被低估的Cathie Wood股票现在比特斯拉更值得买入吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197074607","media":"Motley Fool","summary":"It definitely could have more upside potential.Pretty much everybody knows Cathie Wood really likesT","content":"It definitely could have more upside potential.Pretty much everybody knows Cathie Wood really likesTesla(NASDAQ:TSLA). The ARK Investment Management founder and CEO talks about Tesla regularly. And when the electric-vehicle stock dips, Wood usually buys even more for her high-flying exchange-traded funds.<blockquote>它肯定有更多的上升潜力。几乎每个人都知道凯西·伍德真的很喜欢特斯拉（纳斯达克：TSLA）。方舟投资管理公司创始人兼首席执行官经常谈论特斯拉。当电动汽车股票下跌时，伍德通常会为她雄心勃勃的交易所交易基金购买更多股票。</blockquote>Many of the other holdings in the ETFs managed by Wood don't receive as much attention. However, she pointed to one of them earlier this month in a CNBC interview, referring to it as one of the \"most underappreciated\" stocks that she owns.<blockquote>伍德管理的ETF中的许多其他持股并没有受到那么多关注。然而，她本月早些时候在接受CNBC采访时指出了其中一只股票，称其为她拥有的“最被低估”的股票之一。</blockquote>What is this underappreciated stock -- and could it be an even better buy than Tesla?<blockquote>这只被低估的股票是什么——它是否比特斯拉更值得买入？</blockquote>It's in the genes<blockquote>这是基因里的</blockquote>Wood singled out medical genetics leaderInvitae(NYSE:NVTA)as an especially underappreciated stock. The company states that its mission \"is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.\"<blockquote>伍德特别提到了医学遗传学领导者邀请（纽约证券交易所股票代码：NVTA）是一只特别被低估的股票。该公司表示，其使命“是将全面的遗传信息带入主流医学，以改善数十亿人的医疗保健。”</blockquote>That's the kind of ambitious goal that excites Cathie Wood. It's not surprising, therefore, that two of the ETFs that she manages have positions in Invitae. The stock is the 11th-largest holding in theARK Innovation ETFand the 17th-largest holding in theARK Genomic Revolution ETF.<blockquote>这就是让凯西·伍德兴奋的雄心勃勃的目标。因此，她管理的两只ETF持有Invitae的头寸也就不足为奇了。该股是该公司第11大持股方舟创新ETF和第17大持股方舟基因组革命ETF.</blockquote>Invitae offers a wide range of genetic testing. Individuals can determine their risks of passing on genetic conditions to children and the most suitable embryos to help ensure a healthy pregnancy can be identified during in vitro fertilization. Healthcare providers can order genetic diagnostics tests for an extensive and growing list of conditions.<blockquote>Invitae提供广泛的基因检测。个人可以确定他们将遗传疾病遗传给孩子的风险，以及最合适的胚胎，以帮助确保在体外受精过程中确定健康怀孕。医疗保健提供者可以为越来越多的疾病订购基因诊断测试。</blockquote>Over the last five years, Invitae's trailing-12-month revenue has skyrocketed over 2,400%. That performance trounces Tesla's revenue growth of around 640% during the same period.<blockquote>在过去五年中，Invitae过去12个月的收入猛增了2,400%以上。这一业绩超过了特斯拉同期约640%的收入增长。</blockquote>Unlike Tesla, however, Invitae isn't profitable yet. But the genetic testing companyhas a path to profitabilityover the next few years, especially with the recent acquisitions of ArcherDX and One Codex expanding Invitae's capabilities.<blockquote>然而，与特斯拉不同的是，Invitae尚未盈利。但这家基因检测公司在未来几年内有一条盈利之路，特别是随着最近收购ArcherDX和One Codex扩大Invitae的能力。</blockquote>A massive potential market<blockquote>巨大的潜在市场</blockquote>In the past, the high costs of genetic testing served as a limiting factor for growth in the market. But technological innovations in gene sequencing have reduced the costs of testing and opened the door to a massive potential market.<blockquote>过去，基因检测的高成本是市场增长的限制因素。但基因测序的技术创新降低了检测成本，打开了巨大潜在市场的大门。</blockquote>Invitae CEO Sean George told CNBC last week that the scenario for genetic testing is similar to what happened in the computing and networking industry around four decades ago. Lower semiconductor costs back then set the stage for an explosion in the market.<blockquote>Invitae首席执行官肖恩·乔治(Sean George)上周告诉CNBC，基因检测的情况与大约四十年前计算和网络行业发生的情况类似。当时较低的半导体成本为市场爆炸奠定了基础。</blockquote>How big could the explosion be in genetic testing? Invitae thinks that its total addressable market tops $150 billion annually. It projects that the genetic testing opportunity in senior adults ages 65 and over alone is around $63 billion. The company estimates that the potential genetic-testing market in adults between the ages of 41 and 65 totals around $60 billion.<blockquote>基因检测的爆炸会有多大？Invitae认为其潜在市场总额每年超过1500亿美元。它预计，仅65岁及以上老年人的基因检测机会就约为630亿美元。该公司估计，41岁至65岁成年人的潜在基因检测市场总额约为600亿美元。</blockquote>Invitae believes that it's at an inflection point in the transformation curve for genetic testing. As the company continues to drive costs lower and expands its menu of tests, it expects testing volumes to increase significantly.<blockquote>Invitae认为，它正处于基因检测转型曲线的拐点。随着该公司继续降低成本并扩大测试菜单，预计测试量将大幅增加。</blockquote>Better than Tesla?<blockquote>比特斯拉好？</blockquote>To be sure, Invitae hasn't been as big of a winner as Tesla so far. Over the last five years, thehealthcare stockhas quintupled in value. During the same period, however, Tesla skyrocketed close to 1,500%.<blockquote>可以肯定的是，到目前为止，Invitae还没有像特斯拉那样成为大赢家。在过去五年中，医疗保健股的价值增长了五倍。然而，在同一时期，特斯拉飙升了近1500%。</blockquote>But could Invitae be a better pick than Tesla over the long run? When asked in a Bloomberg interview in December which stock could fuel the biggest gains for ARK ETFs over the next five years, Wood acknowledged that Tesla is in the running. However, she also stated, \"The biggest upside surprises are going to come from the genomics space.\"<blockquote>但从长远来看，Invitae会比特斯拉更好吗？当在去年12月接受彭博社采访时被问及哪只股票可能在未来五年内推动ARK ETF的最大涨幅时，伍德承认特斯拉是其中之一。然而，她也表示，“最大的惊喜将来自基因组学领域。”</blockquote>That doesn't mean Invitae is necessarily the genomics stock that will emerge as the major surprise winner of the future. It could be, though.<blockquote>这并不意味着Invitae一定是将成为未来主要意外赢家的基因组学股票。不过，也有可能。</blockquote>The company's market cap currently stands at only around $8.5 billion. Invitae could potentially be a 10-bagger if it snags a double-digit share of its addressable market. While Tesla has been remarkably successful, it's a stretch to envision the stock becoming a 10-bagger again.<blockquote>该公司的市值目前仅为85亿美元左右。如果Invitae在其目标市场中占据两位数的份额，它可能会成为10家企业。尽管特斯拉取得了巨大的成功，但想象该股再次成为10袋股还有些牵强。</blockquote>Invitae just might be a better buy than Tesla right now. Even if it's not, though, there's a really good chance the stock won't remain underappreciated for too much longer.<blockquote>现在Invitae可能比特斯拉更划算。不过，即使事实并非如此，该股也很有可能不会在太长时间内保持低估状态。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?<blockquote>这只被低估的Cathie Wood股票现在比特斯拉更值得买入吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?<blockquote>这只被低估的Cathie Wood股票现在比特斯拉更值得买入吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-03-19 19:10\n\n</h4>\n</header>\n<article>\nIt definitely could have more upside potential.Pretty much everybody knows Cathie Wood really likesTesla(NASDAQ:TSLA). The ARK Investment Management founder and CEO talks about Tesla regularly. And when the electric-vehicle stock dips, Wood usually buys even more for her high-flying exchange-traded funds.<blockquote>它肯定有更多的上升潜力。几乎每个人都知道凯西·伍德真的很喜欢特斯拉（纳斯达克：TSLA）。方舟投资管理公司创始人兼首席执行官经常谈论特斯拉。当电动汽车股票下跌时，伍德通常会为她雄心勃勃的交易所交易基金购买更多股票。</blockquote>Many of the other holdings in the ETFs managed by Wood don't receive as much attention. However, she pointed to one of them earlier this month in a CNBC interview, referring to it as one of the \"most underappreciated\" stocks that she owns.<blockquote>伍德管理的ETF中的许多其他持股并没有受到那么多关注。然而，她本月早些时候在接受CNBC采访时指出了其中一只股票，称其为她拥有的“最被低估”的股票之一。</blockquote>What is this underappreciated stock -- and could it be an even better buy than Tesla?<blockquote>这只被低估的股票是什么——它是否比特斯拉更值得买入？</blockquote>It's in the genes<blockquote>这是基因里的</blockquote>Wood singled out medical genetics leaderInvitae(NYSE:NVTA)as an especially underappreciated stock. The company states that its mission \"is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.\"<blockquote>伍德特别提到了医学遗传学领导者邀请（纽约证券交易所股票代码：NVTA）是一只特别被低估的股票。该公司表示，其使命“是将全面的遗传信息带入主流医学，以改善数十亿人的医疗保健。”</blockquote>That's the kind of ambitious goal that excites Cathie Wood. It's not surprising, therefore, that two of the ETFs that she manages have positions in Invitae. The stock is the 11th-largest holding in theARK Innovation ETFand the 17th-largest holding in theARK Genomic Revolution ETF.<blockquote>这就是让凯西·伍德兴奋的雄心勃勃的目标。因此，她管理的两只ETF持有Invitae的头寸也就不足为奇了。该股是该公司第11大持股方舟创新ETF和第17大持股方舟基因组革命ETF.</blockquote>Invitae offers a wide range of genetic testing. Individuals can determine their risks of passing on genetic conditions to children and the most suitable embryos to help ensure a healthy pregnancy can be identified during in vitro fertilization. Healthcare providers can order genetic diagnostics tests for an extensive and growing list of conditions.<blockquote>Invitae提供广泛的基因检测。个人可以确定他们将遗传疾病遗传给孩子的风险，以及最合适的胚胎，以帮助确保在体外受精过程中确定健康怀孕。医疗保健提供者可以为越来越多的疾病订购基因诊断测试。</blockquote>Over the last five years, Invitae's trailing-12-month revenue has skyrocketed over 2,400%. That performance trounces Tesla's revenue growth of around 640% during the same period.<blockquote>在过去五年中，Invitae过去12个月的收入猛增了2,400%以上。这一业绩超过了特斯拉同期约640%的收入增长。</blockquote>Unlike Tesla, however, Invitae isn't profitable yet. But the genetic testing companyhas a path to profitabilityover the next few years, especially with the recent acquisitions of ArcherDX and One Codex expanding Invitae's capabilities.<blockquote>然而，与特斯拉不同的是，Invitae尚未盈利。但这家基因检测公司在未来几年内有一条盈利之路，特别是随着最近收购ArcherDX和One Codex扩大Invitae的能力。</blockquote>A massive potential market<blockquote>巨大的潜在市场</blockquote>In the past, the high costs of genetic testing served as a limiting factor for growth in the market. But technological innovations in gene sequencing have reduced the costs of testing and opened the door to a massive potential market.<blockquote>过去，基因检测的高成本是市场增长的限制因素。但基因测序的技术创新降低了检测成本，打开了巨大潜在市场的大门。</blockquote>Invitae CEO Sean George told CNBC last week that the scenario for genetic testing is similar to what happened in the computing and networking industry around four decades ago. Lower semiconductor costs back then set the stage for an explosion in the market.<blockquote>Invitae首席执行官肖恩·乔治(Sean George)上周告诉CNBC，基因检测的情况与大约四十年前计算和网络行业发生的情况类似。当时较低的半导体成本为市场爆炸奠定了基础。</blockquote>How big could the explosion be in genetic testing? Invitae thinks that its total addressable market tops $150 billion annually. It projects that the genetic testing opportunity in senior adults ages 65 and over alone is around $63 billion. The company estimates that the potential genetic-testing market in adults between the ages of 41 and 65 totals around $60 billion.<blockquote>基因检测的爆炸会有多大？Invitae认为其潜在市场总额每年超过1500亿美元。它预计，仅65岁及以上老年人的基因检测机会就约为630亿美元。该公司估计，41岁至65岁成年人的潜在基因检测市场总额约为600亿美元。</blockquote>Invitae believes that it's at an inflection point in the transformation curve for genetic testing. As the company continues to drive costs lower and expands its menu of tests, it expects testing volumes to increase significantly.<blockquote>Invitae认为，它正处于基因检测转型曲线的拐点。随着该公司继续降低成本并扩大测试菜单，预计测试量将大幅增加。</blockquote>Better than Tesla?<blockquote>比特斯拉好？</blockquote>To be sure, Invitae hasn't been as big of a winner as Tesla so far. Over the last five years, thehealthcare stockhas quintupled in value. During the same period, however, Tesla skyrocketed close to 1,500%.<blockquote>可以肯定的是，到目前为止，Invitae还没有像特斯拉那样成为大赢家。在过去五年中，医疗保健股的价值增长了五倍。然而，在同一时期，特斯拉飙升了近1500%。</blockquote>But could Invitae be a better pick than Tesla over the long run? When asked in a Bloomberg interview in December which stock could fuel the biggest gains for ARK ETFs over the next five years, Wood acknowledged that Tesla is in the running. However, she also stated, \"The biggest upside surprises are going to come from the genomics space.\"<blockquote>但从长远来看，Invitae会比特斯拉更好吗？当在去年12月接受彭博社采访时被问及哪只股票可能在未来五年内推动ARK ETF的最大涨幅时，伍德承认特斯拉是其中之一。然而，她也表示，“最大的惊喜将来自基因组学领域。”</blockquote>That doesn't mean Invitae is necessarily the genomics stock that will emerge as the major surprise winner of the future. It could be, though.<blockquote>这并不意味着Invitae一定是将成为未来主要意外赢家的基因组学股票。不过，也有可能。</blockquote>The company's market cap currently stands at only around $8.5 billion. Invitae could potentially be a 10-bagger if it snags a double-digit share of its addressable market. While Tesla has been remarkably successful, it's a stretch to envision the stock becoming a 10-bagger again.<blockquote>该公司的市值目前仅为85亿美元左右。如果Invitae在其目标市场中占据两位数的份额，它可能会成为10家企业。尽管特斯拉取得了巨大的成功，但想象该股再次成为10袋股还有些牵强。</blockquote>Invitae just might be a better buy than Tesla right now. Even if it's not, though, there's a really good chance the stock won't remain underappreciated for too much longer.<blockquote>现在Invitae可能比特斯拉更划算。不过，即使事实并非如此，该股也很有可能不会在太长时间内保持低估状态。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/03/19/is-this-underappreciated-cathie-wood-stock-a-bette/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/19/is-this-underappreciated-cathie-wood-stock-a-bette/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197074607","content_text":"It definitely could have more upside potential.Pretty much everybody knows Cathie Wood really likesTesla(NASDAQ:TSLA). The ARK Investment Management founder and CEO talks about Tesla regularly. And when the electric-vehicle stock dips, Wood usually buys even more for her high-flying exchange-traded funds.Many of the other holdings in the ETFs managed by Wood don't receive as much attention. However, she pointed to one of them earlier this month in a CNBC interview, referring to it as one of the \"most underappreciated\" stocks that she owns.What is this underappreciated stock -- and could it be an even better buy than Tesla?It's in the genesWood singled out medical genetics leaderInvitae(NYSE:NVTA)as an especially underappreciated stock. The company states that its mission \"is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.\"That's the kind of ambitious goal that excites Cathie Wood. It's not surprising, therefore, that two of the ETFs that she manages have positions in Invitae. The stock is the 11th-largest holding in theARK Innovation ETFand the 17th-largest holding in theARK Genomic Revolution ETF.Invitae offers a wide range of genetic testing. Individuals can determine their risks of passing on genetic conditions to children and the most suitable embryos to help ensure a healthy pregnancy can be identified during in vitro fertilization. Healthcare providers can order genetic diagnostics tests for an extensive and growing list of conditions.Over the last five years, Invitae's trailing-12-month revenue has skyrocketed over 2,400%. That performance trounces Tesla's revenue growth of around 640% during the same period.Unlike Tesla, however, Invitae isn't profitable yet. But the genetic testing companyhas a path to profitabilityover the next few years, especially with the recent acquisitions of ArcherDX and One Codex expanding Invitae's capabilities.A massive potential marketIn the past, the high costs of genetic testing served as a limiting factor for growth in the market. But technological innovations in gene sequencing have reduced the costs of testing and opened the door to a massive potential market.Invitae CEO Sean George told CNBC last week that the scenario for genetic testing is similar to what happened in the computing and networking industry around four decades ago. Lower semiconductor costs back then set the stage for an explosion in the market.How big could the explosion be in genetic testing? Invitae thinks that its total addressable market tops $150 billion annually. It projects that the genetic testing opportunity in senior adults ages 65 and over alone is around $63 billion. The company estimates that the potential genetic-testing market in adults between the ages of 41 and 65 totals around $60 billion.Invitae believes that it's at an inflection point in the transformation curve for genetic testing. As the company continues to drive costs lower and expands its menu of tests, it expects testing volumes to increase significantly.Better than Tesla?To be sure, Invitae hasn't been as big of a winner as Tesla so far. Over the last five years, thehealthcare stockhas quintupled in value. During the same period, however, Tesla skyrocketed close to 1,500%.But could Invitae be a better pick than Tesla over the long run? When asked in a Bloomberg interview in December which stock could fuel the biggest gains for ARK ETFs over the next five years, Wood acknowledged that Tesla is in the running. However, she also stated, \"The biggest upside surprises are going to come from the genomics space.\"That doesn't mean Invitae is necessarily the genomics stock that will emerge as the major surprise winner of the future. It could be, though.The company's market cap currently stands at only around $8.5 billion. Invitae could potentially be a 10-bagger if it snags a double-digit share of its addressable market. While Tesla has been remarkably successful, it's a stretch to envision the stock becoming a 10-bagger again.Invitae just might be a better buy than Tesla right now. Even if it's not, though, there's a really good chance the stock won't remain underappreciated for too much longer.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":931,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/350922374"}